Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Stage II III NSCLC Adjuvant Afatinib Trial Ended Early, What Did We Learn About Adjuvant Targeted Therapy
Post ASCO 2019 Lung Cancer Round Table Discussion - Stage II III NSCLC Adjuvant Afatinib Trial Ended Early, What Did We Learn About Adjuvant Targeted Therapy
Author
Howard (Jack) West, MD
Image

We are excited to share with you a recent series of discussions between Drs. Howard (Jack) West, MD, Associate Clinical Professor, Medical Oncology, Executive Director, Employer Services at City of Hope Comprehensive Cancer Center, and Founder, President and CEO Of GRACE, Charu Aggarwal, MD, MPH with the Perelman Center for Advanced Medicine, University of Pennsylvania, and Benjamin Levy MD, Clinical Director Of Medical Oncology, Assistant Professor Of Oncology at the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital.

The doctors recently collaborated from their respective geographical locations to review top discussion points from Lung Cancer from ASCO 2019.  In this video, the doctors discuss the following: "Stage II III NSCLC  Adjuvant Afatinib Trial Ended Early,  What Did We Learn About Adjuvant Targeted Therapy".

 

Please visit our community forums with any questions or comments! 


 

 
Video Language

Next Previous link

Previous PostNext Post

Related Content

Image
2025 Spanish Targeted Therapy in Lung Cancer Patient Forum
Article
Da click aquí para más información y para registrarte ahora
Image
Clinical Trials Storytelling 2025
Article
GRACE is pleased to introduce three amazing individuals participating in the 2024-25 GRACE Clinical Trials Experiences Storytelling Program
Article
Advance directives are a powerful way to take control of healthcare choices. These documents allow you to outline preferences for medical care and specify end-of-life wishes. These documents can also be a way to appoint loved ones who you would like to help with these decisions, such as a healthcare proxy (someone to make decisions on your behalf, if you cannot). As cancer treatments can involve aggressive treatments and/or complex medical management, having advance directives ensures that your desires regarding treatment options and end-of-life care are clearly communicated.